PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
In March 2021, Myovant Sciences (Myovant) and Pfizer announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 The study was designed to assess the safety and efficacy of continued treatment with relugolix combination therapy for up to two years.
40 
Let's personalize your content